Sagimet Biosciences enters $75M ATM equity facility with Leerink Partners, terminates prior Cantor facility

Sagimet Biosciences Inc.

Up to $75M in common stock may be sold from time to time via at-the-market offerings through Leerink Partners.
Agent commission of up to 3.0% on gross proceeds from sales under the agreement.
Prior Cantor Fitzgerald ATM agreement terminated effective Aug 14, 2025; no shares were sold under that facility.

item 1.01item 1.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.